Malkoun N, Fotso MJ, Cartier L, Forest F, Auberdiac P, Chargari C, Thorin J, Pacaut C, Peoc'h M, Nuti C, Schmitt T, Magné N. [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
Cancer Radiother 2011;
15:202-7. [PMID:
21450506 DOI:
10.1016/j.canrad.2010.11.015]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2010] [Revised: 10/25/2010] [Accepted: 11/04/2010] [Indexed: 10/18/2022]
Abstract
PURPOSE
Temozolomide has significantly improved the outcome of patients with glioblastoma. However, the optimal duration of continuation treatment after chemoradiation remains uncertain. This retrospective analysis aims at assessing the feasibility, the tolerance, and the potential benefit of prolonging adjuvant temozolomide more than six months, which is the reference protocol.
PATIENTS AND METHODS
Forty-six patients were included in the analysis. Median age at diagnosis was 61 years old (range 40 to 77). Forty-five patients received a conformal external beam radiation with concurrent temozolomide-based chemotherapy. Then, 37 patients received adjuvant chemotherapy with temozolomide. The treatment was continued until progression or toxicity.
RESULTS
During the adjuvant phase, no treatment discontinuation for toxicity was necessary. Eight patients required dose adaptation because of toxicity. Thirty-two patients presented tumor progression during the adjuvant phase. Overall median survival was 12.3 months (range 11-13.2 months) and progression-free survival (PFS) was 7.6 months (range 5.6-9.6 months).
CONCLUSION
These results suggest feasibility of delivering temozolomide beyond the six months of the standard protocol, with mild toxicity and survival data at least comparable to those from literature. Prospective assessments are ongoing.
Collapse